Barlis, Kalliope – Trademark Portfolio

Entity Type: 01

Barlis, Kalliope holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 44 (Medical Services) — 2 filings in this category. The portfolio also extends into Class 41 (Education & Entertainment) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include NEURO-LINGUISTIC ACUPUNCTURE. The owner is based in Long Island City, NY.

Long Island City, NY 11104

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Barlis, Kalliope's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

44
Medical Services (2 filings)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

41
Education & Entertainment (1 filing)

Education; providing of training; entertainment; sporting and cultural activities

Frequently Asked Questions

How many trademarks does Barlis, Kalliope have?

Barlis, Kalliope has 3 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 abandoned, 1 cancelled.

What trademark classes does Barlis, Kalliope file in?

Barlis, Kalliope files trademarks across 2 Nice Classification classes. The most active classes are Class 44 (Medical Services), Class 41 (Education & Entertainment). Class 44 covers medical services; veterinary services; hygienic and beauty care for human beings or animals.

What are Barlis, Kalliope's most well-known trademarks?

Barlis, Kalliope's registered trademark portfolio includes well-known marks such as NEURO-LINGUISTIC ACUPUNCTURE. These are among 1 currently registered trademark in the portfolio.

What is Barlis, Kalliope's trademark registration success rate?

Barlis, Kalliope has a 33% trademark registration rate, with 1 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.